Dong-A ST introduces a new antiviral with Japanese TAKARA BIO INC

Published: 2018-08-27 17:54:53

Updated: 2018-08-27 17:54:53

Dong-A ST(CEO/President Dae-Shik Eom) announced on the 23^rd that they signed an agreement to introduce a new antiviral with a Japanese biotechnology company TAKARA BIO INC(CEO Nakao Koichi), which develops gene and cell therapies, in Tokyo, Japan on the 22^nd.

Under the agreement, Dong-A ST will own the Korean exclusive development and sales rights of Canerpaturev(C-REV), a new antiviral that T...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.